

**TORRENT PHARMACEUTICALS LIMITED**

**AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED ON 30TH SEPTEMBER, 2007**

[ Rs. in lacs except per share data ]

PARTICULARS	THREE MONTHS ENDED ON		SIX MONTHS ENDED ON		ACCOUNTING YEAR ENDED ON
	30-09-2007	30-09-2006	30-09-2007	30-09-2006	31-03-2007
Sales (net of Sales Tax / VAT ) (see note 3)	25461	22974	49939	44481	87851
Less: Excise Duty collected	157	268	328	894	1226
Net Sales	25304	22706	49611	43587	86625
Other Operating Income	573	309	899	538	1665
Other Income	78	1	103	7	237
<b>Total Income</b>	<b>25955</b>	<b>23016</b>	<b>50613</b>	<b>44132</b>	<b>88527</b>
<b>Expenditure</b>					
(Increase)/Decrease in Stock in Trade	817	(1313)	269	(2145)	(3078)
Consumption of Raw/Packing Materials	7329	7578	14304	14524	26801
Purchase of Traded Goods	1181	2282	3194	3738	7620
Employees Cost	2950	3250	6025	5692	11067
Research and Development Expenses	2419	2097	4451	3258	7396
Depreciation and Amortization	837	752	1649	1475	3024
Other Expenditure	5692	5268	11778	10348	21972
<b>Total Expenditure</b>	<b>21225</b>	<b>19914</b>	<b>41670</b>	<b>36890</b>	<b>74802</b>
Net Borrowing Costs	457	125	848	390	1315
<b>Profit from Ordinary Activities before tax</b>	<b>4273</b>	<b>2977</b>	<b>8095</b>	<b>6852</b>	<b>12410</b>
Tax expenses	542	413	1041	1146	1114
<b>Net Profit from Ordinary Activities after tax</b>	<b>3731</b>	<b>2564</b>	<b>7054</b>	<b>5706</b>	<b>11296</b>
Paid-up Equity Share Capital [Face Value Rs.5]	4231	4231	4231	4231	4231
Reserves excluding Revaluation Reserves	-	-	-	-	42207
Basic and Diluted EPS for the period	4.41	3.03	8.34	6.74	13.35
Public shareholding					
Number of shares	21919832	-	-	-	21919832
Percentage of shareholding	25.91%	-	-	-	25.91%

**Notes to Stand-alone Audited Results :**

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors, in their respective meetings held on 30-Oct-07. There is no qualification in the Auditors Report on this statement of financial results.
- 2 The figures for the comparative periods have been regrouped, wherever necessary, to render them comparable with the figures for the current periods.
- 3 The Company operates a solitary business segment viz. pharmaceuticals, comprising mainly manufacture of branded formulations. A further breakdown of pharmaceutical sales is given below.

Particulars	Rs. in lacs						
	Quarter ended			Half Year Ended			Year ended
	30-Sep-07	30-Sep-06	Growth %	30-Sep-07	30-Sep-06	Growth %	31-Mar-07
Domestic Formulations	15350	15214	1%	32524	30013	8%	55665
Exports	5626	4376	29%	9876	8287	19%	20168
Contract Manufacture	4405	3354	31%	7406	6084	22%	11850
Others	80	30	-	133	97	-	168
<b>Gross Sales</b>	<b>25461</b>	<b>22974</b>	<b>11%</b>	<b>49939</b>	<b>44481</b>	<b>12%</b>	<b>87851</b>
Less : Excise duty	157	268	-	328	894	-	1226
<b>Net Sales</b>	<b>25304</b>	<b>22706</b>	<b>11%</b>	<b>49611</b>	<b>43587</b>	<b>14%</b>	<b>86625</b>

- 4 The Company borrowed secured long term loan of Rs. 8080 lacs during the current quarter.
- 5 During the current quarter, the following investments were made:
  - (a) Additional investment of Rs. 214 lacs in equity shares of Torrent Pharma Inc., its wholly owned subsidiary in U.S.A.
  - (b) Investment of Rs. 1893 lacs in equity shares of GPC Cayman Investors I Ltd., (GPI), a joint venture company incorporated in Cayman Islands. GPI will invest in a start-up business which will build a low cost generic drug manufacturing platform in China. The investment represents an approximate 7% equity stake in the business.
- 6 During the quarter, 3 investor complaints were received and resolved. No complaints were pending either at the beginning or at the end of the quarter.
- 7 The Company has also prepared and published unaudited consolidated financial results for the quarter and half year, which were subjected to limited review by the statutory auditors of the Company.

Place : Ahmedabad  
Date : 30-Oct-07

SUDHIR MEHTA  
Chairman

.... Visit us at [www.torrentpharma.com](http://www.torrentpharma.com)....